Filing Flows

Filing Flows › Cytek Biosciences (CTKB) › Next earnings date

Cytek Biosciences (CTKB) earnings: beat the estimate

Cytek Biosciences (CTKB) reported on Nov 4, 2026 and beat the EPS estimate: −$0.05 against −$0.07 (+28.6%). Revenue was $53.2M for Q3 2026, +2% year over year. It beat the EPS estimate in 20% of the quarters on record.

Last result+28.6% vs estimate
Beat rate20%

The last report

Cytek Biosciences reported revenue of $53.2M for the third quarter 2026 (+2% Y/Y), net loss $6.1M: Product $37.2M, Service $16.1M. How it makes money → · Every quarter →

Cytek Biosciences: EPS against the estimate, last 5 reportsCytek Biosciences: EPS against the estimate, last 5 reportsEstimateReported$0.01−$0.00Nov 25$0.01−$0.29Feb 26−$0.08−$0.10May 26−$0.02−$0.03Aug 26−$0.07−$0.05Nov 26
Latest (Nov 26): Estimate −$0.07, Reported −$0.05.

Cytek Biosciences' latest quarter

Cytek Biosciences, Q3 2026: revenue $53.2M (+2% year over year), operating margin -15.8%, net loss $6.1M, operating cash flow −$4.5M. The chart follows the revenue to costs, profit and cash.

Questions

Did Cytek Biosciences beat earnings?

Cytek Biosciences (CTKB) reported on Nov 4, 2026 and beat the EPS estimate: −$0.05 against −$0.07 (+28.6%).

When does CTKB report earnings?

The next date is not set yet.

Does Cytek Biosciences usually beat earnings?

It beat the consensus EPS estimate in 20% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.